Dr. Gurpreet Singh Padda argues Alzheimer’s decline starts with brain energy failure

On World Alzheimer’s Day, Dr. Gurpreet Singh Padda says cognitive decline may be driven more by fuel shortage, inflammation and metabolic dysfunction than by amyloid plaque alone. The argument points to measurable factors like glucose metabolism, B-vitamin status and insulin resistance as earlier signals that could change how clinicians screen for risk.

Why it matters: - Dr. Gurpreet Singh Padda is pushing a broader view of Alzheimer’s disease that could shift attention from plaque removal to earlier metabolic screening. - The argument centers on factors that are measurable in primary care, including glucose control, insulin sensitivity, B-vitamin status, inflammatory load and sleep. - If the framing holds, it suggests cognitive decline may be detectable years or decades before a formal Alzheimer’s diagnosis.

What happened: - On World Alzheimer’s Day, Dr. Padda, a board-certified physician and author of The Starved Brain, highlighted research linking cognitive decline to brain energy failure and systemic inflammation. - Padda said the field has focused on amyloid plaques for 30 years, but plaque-clearing therapies have delivered results that are modest relative to the investment. - Padda framed the problem as potentially diagnostic rather than purely pharmacological.

The details: - The adult brain is about 2% of body weight and uses close to 20% of resting energy expenditure. - Reduced cerebral glucose metabolism appears early in Alzheimer’s risk, including in asymptomatic APOE4 carriers in their 20s and 30s. - Later research found apolipoprotein E, not fibrillar amyloid, accounted for reduced glucose metabolism in normal aging. - Researchers led by Stephen Cunnane found that brain glucose uptake is about 20% to 25% lower in Alzheimer’s disease, while ketone uptake remains essentially preserved. - That pattern suggests neurons in hypometabolic regions may still be alive but starved for fuel. - Thiamine diphosphate reduction correlates strongly with brain glucose hypometabolism, while amyloid deposition does not. - The insulin-degrading enzyme clears both insulin and amyloid-beta, creating a mechanistic link between metabolic dysfunction and amyloid buildup. - In chronic hyperinsulinemia, amyloid clearance may slow because the shared enzyme is saturated by insulin. - Padda said this supports the idea that plaque may be a downstream consequence of systemic metabolic dysfunction rather than a primary cause. - Padda also said the clinical weight of the enzyme-competition hypothesis remains debated. - The Oxford VITACOG trial randomized 271 people over 70 with mild cognitive impairment to high-dose folic acid, B6 and B12 or placebo for two years. - Among 168 participants with serial MRI, whole-brain atrophy was 0.76% per year on treatment versus 1.08% on placebo, a 29.6% reduction. - In participants with baseline homocysteine above 13 micromoles per liter, atrophy was 53% lower on treatment. - Follow-up work found the benefit depended on omega-3 status, with B vitamins helping only those with adequate long-chain omega-3 levels. - B12 deficiency is common in older adults and in long-term users of metformin and proton pump inhibitors. - The condition can be identified on a standard blood panel and corrected. - The Starved Brain does not claim to prevent, treat or reverse Alzheimer’s disease. - The book argues for earlier attention to modifiable clinical variables rather than late-stage intervention. - The book runs 10 chapters and is available in Kindle and paperback. - Each chapter ends with a code linking to a free technical supplement at the book’s supplement site.

Between the lines: - The core claim is not that plaque is meaningless, but that plaque may be only one part of a larger metabolic picture. - That matters because a metabolism-first framework pushes clinicians toward testing and correction earlier, before irreversible decline. - The emphasis on measurable factors reflects a practical critique: some risk drivers may be ignored because they are not part of standard Alzheimer’s treatment pathways.

What’s next: - Padda is positioning The Starved Brain as a resource for patients and physicians who want a metabolic lens on cognitive decline. - The free supplements tied to each chapter are being published at thestarvedbrain.com one chapter at a time. - The broader debate over whether metabolic dysfunction is causal, contributory or secondary in Alzheimer’s disease is likely to continue.

The bottom line: - Padda’s message is that Alzheimer’s may be less about one toxic protein and more about an energy system failing long before symptoms make the disease visible.